Concern about drug prices are one of the last issues of bipartisan agreement these days, so it should not come as a surprise that the flurry of activity on the topic this year might threaten even the foundation of the pharmaceutical industry's business model: patents.
Members of the House and Senate have introduced a flurry of bills aiming to change how patents are used to...







